Comparison of the cost to reach A1C targets in patients with type-2 diabetes mellitus on oral antidiabetic agents and either biphasic insulin aspart 70/30 or insulin glargine

被引：0

|

作者：

Cobden, D

Allen, E

Botteman, M

机构：

[1] PharMerit, Bethesda, MD USA

[2] Novo Nordisk Inc, Princeton, NJ USA

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)62953-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

收藏

页码：358 / 358

页数：1

相关论文

共 50 条

[1] Efficacy of biphasic insulin aspart 70/30 in insulin-naive patients with type 2 diabetes mellitus not achieving glycemic targets on oral antidiabetic agents
Garber, Alan J.
Jain, Rajeev
Wahl, Timothy
Moses, Alan
Cao, Anjun
Bressler, Peter
DIABETES, 2006, 55 : A477 - A477
[2] Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US
Ray, J. A.
Valentine, W. J.
Roze, S.
Nicklasson, L.
Cobden, D.
Raskin, P.
Garber, A.
Palmer, A. J.
DIABETES OBESITY & METABOLISM, 2007, 9 (01): : 103 - 113
[3] Comparison of twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents
Raskin, P
Rojas, P
Allen, E
DIABETES, 2004, 53 : A143 - A143
[4] A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis
Rys, P.
Wojciechowski, P.
Siejka, S.
Malecki, P.
Hak, L.
Malecki, M. T.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (03) : 304 - 313
[5] Long-term evaluation of the cost-effectiveness of biphasic insulin aspart 30 versus insulin glargine in poorly controlled patients with type 2 diabetes receiving oral antidiabetic agents
Cobden, D
Palmer, A
Nicklasson, L
Roze, S
Garber, A
DIABETOLOGIA, 2005, 48 : A336 - A336
[6] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
DIABETES, 2006, 55 : A123 - A123
[7] Cost to reach target HbA1c in poorly controlled patients with type 2 diabetes mellitus on either biphasic insulin aspart 30 and metformin or a maximized oral hypoglycaemic regimen
Botteman, M
Cobden, D
Nicklasson, L
DIABETOLOGIA, 2005, 48 : A334 - A335
[8] Comparative evaluation of the long-term cost-effectiveness of biphasic insulin aspart 30 and insulin glargine in a sub-population of poorly controlled patients with Type-2 diabetes receiving oral antidiabetic agents
Cobden, D
Nicklasson, L
Raskin, P
Garber, A
Ray, JA
Valentine, W
Palmer, A
Roze, S
VALUE IN HEALTH, 2005, 8 (06) : A162 - A162
[9] Patients with type 2 diabetes not achieving glycemic targets on OADs with/without basal insulin can reach HbA1c targets with biphasic insulin aspart 30/70
Jain, R
Braceras, R
Wahl, T
Wahlen, J
Bressler, P
Deng, L
Garber, A
DIABETOLOGIA, 2005, 48 : A304 - A304
[10] Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin aspart 70/30 before supper
Jain, R
Wahl, T
Wahlen, J
Bressler, P
Hu, P
Allen, E
DIABETES, 2004, 53 : A130 - A130

← 1 2 3 4 5 →